Similar articles for PMID: 28399521

Year	Number of Results
1994	1
1996	1
1997	2
1998	2
1999	2
2000	8
2001	4
2002	5
2003	9
2004	4
2005	4
2006	8
2007	8
2008	8
2009	4
2010	3
2011	14
2012	20
2013	20
2014	15
2015	20
2016	20
2017	17
2018	10
2019	7
2020	13
2021	17
2022	25
2023	12
2024	0

1

Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.

Niedersüss-Beke D, Puntus T, Kunit T, Grünberger B, Lamche M, Loidl W, Böhm R, Kraischits N, Kudlacek S, Schramek P, Meran JG. Niedersüss-Beke D, et al. Oncology. 2017;93(1):36-42. doi: 10.1159/000463389. Epub 2017 Apr 12. Oncology. 2017. PMID: 28399521 Clinical Trial.

2

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.

Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Galsky MD, et al. Cancer. 2015 Aug 1;121(15):2586-93. doi: 10.1002/cncr.29387. Epub 2015 Apr 14. Cancer. 2015. PMID: 25872978 Free article.

3

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.

Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Eur Urol. 2021 Feb;79(2):214-221. doi: 10.1016/j.eururo.2020.08.024. Epub 2020 Aug 28. Eur Urol. 2021. PMID: 32868138 Clinical Trial.

4

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.

Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. Dash A, et al. Cancer. 2008 Nov 1;113(9):2471-7. doi: 10.1002/cncr.23848. Cancer. 2008. PMID: 18823036 Free PMC article.

5

Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.

Yeshchina O, Badalato GM, Wosnitzer MS, Hruby G, RoyChoudhury A, Benson MC, Petrylak DP, McKiernan JM. Yeshchina O, et al. Urology. 2012 Feb;79(2):384-90. doi: 10.1016/j.urology.2011.10.050. Epub 2011 Dec 22. Urology. 2012. PMID: 22196406

6

Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.

Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W; Collaborators. Zargar H, et al. J Urol. 2018 Jun;199(6):1452-1458. doi: 10.1016/j.juro.2017.12.062. Epub 2018 Jan 9. J Urol. 2018. PMID: 29329894

7

Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.

Weight CJ, Garcia JA, Hansel DE, Fergany AF, Campbell SC, Gong MC, Jones JS, Klein EA, Dreicer R, Stephenson AJ. Weight CJ, et al. Cancer. 2009 Feb 15;115(4):792-9. doi: 10.1002/cncr.24106. Cancer. 2009. PMID: 19127557 Free article.

8

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

van de Putte EE, Mertens LS, Meijer RP, van der Heijden MS, Bex A, van der Poel HG, Kerst JM, Bergman AM, Horenblas S, van Rhijn BW. van de Putte EE, et al. World J Urol. 2016 Feb;34(2):157-62. doi: 10.1007/s00345-015-1636-y. Epub 2015 Jul 17. World J Urol. 2016. PMID: 26184106

9

Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.

Lee Y, Kim YS, Hong B, Cho YM, Lee JL. Lee Y, et al. J Cancer Res Clin Oncol. 2021 Nov;147(11):3421-3429. doi: 10.1007/s00432-021-03582-x. Epub 2021 Mar 14. J Cancer Res Clin Oncol. 2021. PMID: 33715088

10

Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.

Khaled HM, Shafik HE, Zabhloul MS, Ghoneim M, Saber RA, Manie M, Enein HA, Megeed HA, Mansur O, Sherbini ME, Mahran TZ, Kalawee ME, Badran A, Ramadan SM. Khaled HM, et al. Clin Genitourin Cancer. 2014 Oct;12(5):e233-40. doi: 10.1016/j.clgc.2014.04.002. Epub 2014 May 6. Clin Genitourin Cancer. 2014. PMID: 24889794 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

234 results

Results by year